The BRCA1 tumor suppressor protein heterodimerizes with its partner protein, BARD1, via the RING domain present in both proteins. The heterodimer contains an E3 ubiquitin ligase activity and participates in multiple cellular functions such as cell cycle control, DNA repair and regulation of gene transcription, collectively aimed at maintaining genomic stability and tumor suppression. Yet, the precise role of BRCA1 E3 ligase in these cellular functions is poorly understood. We present data showing that BRCA1 ubiquitinates G2/M cell cycle proteins, cyclin B and Cdc25C, leading to their accelerated degradation via a mechanism that is independent of APC/C. BRCA1-dependent degradation of cyclin B and Cdc25C is reversed by proteasome inhibitors and is enhanced following DNA damage, which may represent a possible mechanism to prevent cyclin B and Cdc25C accumulation, a requirement for mitotic entry. Our data provide mechanistic insight into how BRCA1 E3 ligase activity regulates the G2/M cell cycle checkpoint and, thus, contributes to maintenance of genomic stability.
INTRODUCTION
Germline mutations in the BRCA1 tumor suppressor gene predispose women to early-onset breast and ovarian cancer, and account for the majority of familial breast cancer cases. The BRCA1 tumor suppressor is a ubiquitin E3 ligase enzyme that has been implicated in numerous cellular processes essential for maintaining genomic integrity such as regulation of cell cycle checkpoint control, homologous recombination and DNA repair, centrosome amplification, transcription and chromatin dynamics. 1 However, the precise mechanism through which BRCA1 exerts its tumor suppression function is not well understood.
The RING domain at the amino-terminus of BRCA1 protein contains an E3 ubiquitin ligase activity.
2 BRCA1 forms a functional heterodimer with another RING-BRCT domains containing protein, BARD1, and this interaction stabilizes both proteins and enhances their E3 ubiquitin ligase activity. 3, 4 Breast cancer-associated missense mutations at the amino-terminus of BRCA1 eliminate the ubiquitin ligase activity and abrogate the cell cycle checkpoint function of the protein following DNA damage. 5, 6 The DNA damage response is controlled by multiple posttranslational modifications including ubiquitination and sumoylation in addition to phosphorylation cascades. Several E3 ligase entities including RNF8, RNF168, HERC2, RAD18, RNF20/40 and BRCA1/BARD1 are recruited to DNA damage sites where they orchestrate a host of cellular responses including cell cycle arrest and DNA repair (reviewed in Ohta et al. 7 ). For example, the BRCA1/ BARD1 heterodimer is recruited by the RAP80-Abraxas complex to K63-polyubiqiuitin chains at damaged sites through a tandem ubiquitin interactive motif. [8] [9] [10] The BRCA1/BARD1 heterodimer seems the most versatile of these E3 enzymes that populate the damage sites as it can conjugate mono-and polyubiquitinations. To date, the BRCA1-BARD1 complex was found capable of catalyzing monoubiquitination on histones including H2A and H2AX, as well as g-tubulin and estrogen receptor in vitro. 3, 11, 12 Recently Zhu et al 13 demonstrated that BRCA1 ubiquitinates H2A in vivo and this activity contributes to heterochromatin silencing.
BRCA1/BARD1 also catalyzes polyubiquitination on several proteins, including CtIP, NPM/B23 and itself, but this ubiquitination does not signal for protein degradation. [14] [15] [16] [17] BRCA1 was reported to polyubiquitinate several components of the transcriptional machinery: RPB1, RPB8, TFIIE [17] [18] [19] and the hormonally regulated transcription factor, progesterone receptor, 20, 21 suggesting that BRCA1 regulates transcription via ubiquitination. However, except for progesterone receptor the specificity of these reactions could not be confirmed. Thus, despite being the first E3 enzyme recognized at the vicinity of damaged DNA, the contribution of BRCA1-mediated ubiquitination to the DNA damage response is still unclear.
Previously we have shown that following DNA damage, BRCA1 has an essential role in cell cycle arrest at the G2/M boundary at least partially via a mechanism requiring Chk1 kinase activation and downregulation of cyclin B/Cdk1 and Cdc25C. 22, 23 Exactly how BRCA1 downregulates these proteins that are critical for cell cycle progression into mitosis remains to be resolved. It has been shown that missense mutations in the amino-terminus of BRCA1 not only eliminate its ubiquitin ligase activity but also abrogate its cell cycle checkpoint function. 5, 6 Therefore, it seems reasonable that BRCA1-dependent ubiquitination has a role in cell cycle checkpoint activation especially following DNA damage.
Cell cycle progression through the G2/M boundary involves tightly controlled spatial and temporal regulation of cell cycle proteins expression and activity. Cdc25C phosphatase is a mitotic inducer that is required for the activation of the cyclin B1/Cdk1 complex. Cyclin B expression accumulates during S and G2 phases, and it translocates to the nucleus to associate with Cdk1. Both cyclin B and Cdc25C are short-lived proteins whose degradation is temporally regulated. Cyclin B levels are downregulated at metaphase during mitosis and Cdc25C at mitotic exit. Cyclin B ubiquitination and destruction by the proteasome occurs following the recognition of its D (destruction) box when APC/C complexes with Cdc20. 24, 25 Cdc25C contains a KEN box, 26 an APC/C degradation signal (degron), which is recognized by APC/C when it is complexed with Cdh1. 27 Little is known about the mechanism by which these proteins are regulated in the context of mitotic block following DNA damage, as APC/C is inhibited and the spindle assembly checkpoint (SAC) is activated to prevent the accumulation of the mitotic cyclin/Cdk complexes and scheduled mitosis. 25 Here we report that BRCA1 polyubiquitinates cyclin B and Cdc25C and targets them for degradation via the ubiquitin-proteasome pathway to prevent unscheduled mitotic entry following DNA damage. This data contributes to our knowledge of how loss of BRCA1 enhances genomic instability in breast cancer.
RESULTS

Proteasome inhibitors reverse BRCA1-dependent downregulation of cyclin B and Cdc25C
We and others have shown previously that BRCA1 downregulates the expression of cyclin B and Cdc25C. 22, 28 To determine whether BRCA1 regulates the proteolysis of cyclin B and Cdc25C, we expressed full-length wild-type BRCA1 complementary DNA in BRCA1-null HCC1937 cells using an adenoviral vector. Cells were treated with 10 mM of the proteasome inhibitor N-acetyl-leu-leu- Figure 1 . BRCA1 alters expression and turnover of cell cycle proteins. (a) Proteasome inhibitor reverses BRCA1 downregulation of cyclin B and Cdc25C expression. HCC1937 vector and HCC1937-BRCA1 cells were treated with proteasome inhibitor ALLN or solvent for 6 h. Expression of BRCA1 and cell cycle proteins was analyzed by immunoblotting with the indicated antibodies. a-Tubulin reveals equal loading. (b) BRCA1 expression accelerates cyclin B and Cdc25C turnover. HCC1937 control, HCC1937 vector and HCC1937-BRCA1 cells were treated with CHX and collected at the indicated times. Expression of cyclin B and Cdc25C were analyzed by immunoblot. GAPDH reveals equal loading. Representative blots of at least three experiments are shown. (c) HCC1937 vector and HCC1937-BRCA1 cells were exposed to 10 Gy of IR and immediately treated with ALLN for 6 h. The expression of BRCA1 and cell cycle proteins was analyzed by immunoblotting with the indicated antibodies. A representative blot of at least three experiments is shown. *Po0.05. (d) HCC1937 vector and HCC1937-BRCA1 cells were exposed to UCN-01 1 h before 10 Gy of IR. Cells were let to recover for 2 h and expression of cyclin B, Chk1 and phosphorylated Chk1 (S345) was analyzed by immunoblotting with the indicated antibodies. A representative blot of at least 3 experiments is shown. *Po0.05. (e) HCC1937 vector and HCC1937-BRCA1 cells were exposed to 10 Gy of IR and let to recover for the indicated time points and then fixed and stained with propidium iodide. Cell cycle distribution was determined by fluorescence-activated cell sorting as previously described. 22 (f ) Proteasome inhibitor inhibits nuclear destabilization of Cdc25 and cyclin B. BRCA1-deficient and -proficient HCC1937 cells were treated with ALLN 1 h before exposure to IR (6 Gy). Cdc25C and cyclin B immunostaining was performed 5 h following exposure of cells to IR using polyclonal antibody against Cdc25C and a monoclonal antibody to cyclin B. Cells were counterstained with 4 0 6-diamidino-2-phenylindole.
norleucinal (ALLN) or MG132 (data not shown) for 6 h. Expression levels of cyclin B and Cdc25C proteins decreased in HCC1937-BRCA1 cells compared with parental HCC1937 or HCC1937 vector cells ( Figure 1a ). Expression levels were recovered in the presence of proteasome inhibitor, ALLN, in BRCA1-proficient cells, suggesting that BRCA1 is required for targeting cyclin B and Cdc25C degradation via the proteasome. Cdc25A expression increased in response to ALLN, regardless of BRCA1 status (Figure 1a ), suggesting that cyclin B and Cdc25C are specific targets for BRCA1-mediated ubiquitination, whereas Cdc25A degradation is proteasome-dependent but independent of BRCA1.
To determine whether the decreased levels of cyclin B and Cdc25C expression in BRCA1-proficient cells is due to an increased degradation or decreased synthesis, we blocked de-novo protein synthesis with cycloheximide (CHX), and analyzed the rates of cyclin B and Cdc25C decay. The half-life of cyclin B in HCC1937-deficient cells was longer (B3 h) than in HCC1937-BRCA1 cells (o1 h) (Figure 1b) , suggesting that BRCA1 expression destabilizes cyclin B protein. Similar analysis was carried out for Cdc25C levels and suggested that BRCA1 also destabilizes Cdc25C, as the half-life in BRCA1-proficient cells was B2 h whereas it was about three times longer in BRCA1-deficient cells (Figure 1b and Supplementary Figure S1a) .
Consistent with BRCA1 affecting cyclin B and Cdc25C protein stability, no significant differences were detected in mRNA expression of cyclin B and Cdc25C before and after treatment with ALLN in HCC1937 and HCC1937-BRCA1 cells ( Supplementary  Figures S1b and c) .
As BRCA1 is an integral and essential participant of the DNA damage response, 22 we investigated whether BRCA1-mediated proteasomal degradation of cyclin B and Cdc25C is modulated by DNA damage. Following exposure to 10 Gy of ionizing radiation (IR), we observed further downregulation of cyclin B and Cdc25C in IR-treated HCC1937-BRCA1 cells, which was blocked by the pre-treatment with proteasome inhibitor (Figure 1c and Supplementary Figure S2a) . The ribonucleotide reductase inhibitor, hydroxyurea, which causes replication arrest in a BRCA1-dependent context, 23 also promoted a further decline of cyclin B and Cdc25C protein levels in HCC1937-BRCA1 cells relative to HCC1937 vector and control cells that was completely blocked by proteasomal inhibition (Supplementary Figure S2b) . Thus, cyclin B and Cdc25C proteasomal degradation is enhanced in response to DNA damage in a BRCA1-dependent manner. To determine whether downregulation of cyclin B and Cdc25C is mediated via BRCA1 activation of Chk1, BRCA1-deficient and -proficient HCC1937 cells were treated with IR alone or in the presence of Chk1 inhibitor, UCN-01. Chk1 inhibition did not alleviate cyclin B decreased expression following DNA damage, suggesting that Chk1 kinase regulates the activity of cyclin B/Cdk1 complex but not its expression (Figure 1d and Supplementary Figure S2d) . Cell cycle analysis showed accumulation of BRCA1-expressing cells at the G2/M phase only 20-24 h following IR, whereas no significant differences in cell cycle distribution were seen at the earlier time point of 6 h post IR (Figure 1e ). Thus, BRCA1-dependent proteasomal degradation of cyclin B and Cdc25C precede the subsequent BRCA1-dependent cell cycle arrest.
Cyclin B and Cdc25C are spatially regulated and shuttle between the cytoplasm and the nucleus in a cell cycle-dependent manner. In HCC1937-BRCA1 cells, Cdc25C is predominantly expressed in the cytoplasm especially following IR (Figure 1f and Supplementary Figure S3) . 22 This differential distribution of Cdc25C partially reflects the action of 14-3-3s, which shuttles Cdc25C in a BRCA1-regulated manner. 29 Here we show ( Figure 1f ) that IR leads to exclusion of Cdc25C and cyclin B from the nucleus of about 85% of the cells (Supplementary Figure S3) . Treatment with ALLN 1 h before IR prevented such exclusion and Cdc25C and cyclin B were localized in the cytoplasm and the nucleus of naive and irradiated HCC1937-BRCA1 cells. (Figure 1f and Supplementary Figure S3) . Thus, in addition to nuclear export, BRCA1 may target Cdc25C and cyclin B for degradation via the nuclear proteasome and this activity is enhanced following DNA damage.
BRCA1 knockdown stabilizes cyclin B and Cdc25C
To expand our studies, we silenced BRCA1 expression in the breast cancer cell lines MCF7 and BT474 using a specific short hairpin RNA (shRNA)-BRCA1 expression vector. Cyclin B expression levels increased in BRCA1-silenced cells (Figure 2a and Supplementary Figure S4 ) and were comparable to protein levels detected in BRCA1-proficient cells treated with ALLN. Cdc25C protein levels also increased in BRCA1-silenced MCF7 cells compared with the levels seen in MCF7 cells (Figure 2a) . In response to IR, cyclin B and Cdc25C were downregulated in BRCA1-proficient MCF7 cells but no significant changes were noted in BRCA1-silenced cells (Figure 2a ). To determine whether re-expression of BRCA1 in BRCA1-deficient HCC1937 and MCF7-shBRCA1 can rescue cell viability and promote cell survival in response to IR, we carried out an XTT assay and found that shRNA-resistant wild-type BRCA1 can rescue cell survival but the shRNA-resistant ubiquitination mutants of BRCA1: I26A and the RING domain mutant C61G were unable to do so ( Figure 2f ). Collectively, these data show that BRCA1 E3 ligase activity contributes to a radiation-resistant phenotype.
The RING and the BRCT domains are required for BRCA1 ubiquitin ligase activity toward cell cycle proteins To identify the significance of specific BRCA1 functional domains, namely whether the BRCT and/or the serine/threonine phosphorylation cluster (SCD) domains of BRCA1 cooperate with its RING domain in mediating cyclin B and Cdc25C protein degradation, we expressed YFP-tagged fusion constructs linked to the aminoterminus RING domain (1-304 aa fragment, N304) alone or together with the core BRCT domain (aa 1620-1862, C243) or with part of the SCD and BRCT (aa 1470-1862, C393) (Gift of B Henderson; Figure 3a) . Cells expressing the two latter recombinant proteins displayed efficient cell cycle response to IR such as wild-type full-length BRCA1. 30, 31 Cdc25C expression was downregulated only in cells expressing the RING-SCD-BRCT polypeptide, and stabilized following treatment with ALLN as in HCC1937-BRCA1 cells (Figure 3b ). The RING domain alone and the RING-BRCT (C243) were not sufficient to modulate Cdc25C expression. Similarly, the RING-SCD-BRCT polypeptide of BRCA1 was most efficient in modulating cyclin B expression, although the RING-BRCT polypeptide showed some activity as well ( Figure 3b ). Next, we examined whether DNA damage will increase the activity of the BRCA1 recombinant polypeptides, especially of the peptide that contains the damage-induced phosphorylation sites that previously were implicated with BRCA1 cell cycle function. 32 Results presented in Figure 3c show that following IR and ALLN treatment cyclin B and Cdc25C were upregulated in cells that express the RING-SCD-BRCT polypeptide while modestly upregulated in cells that express the RING-BRCT. Interestingly, we noticed that recombinant BRCA1 levels decreased in the presence of the proteasome inhibitor, especially following IR. We considered that BRCA1 polypeptides are either degraded by a proteasomeindependent mechanism or, alternatively, heavily modified by Expression of cyclin B protein was analyzed by immunoblot. GAPDH reveals equal loading. (c) MCF7 cells were transfected with the indicated shRNA and 24 h later were exposed to 10 Gy of IR. Cells were let to recover for the indicated time points and then fixed and stained with propidium iodide. Cell cycle distribution was determined by fluorescence-activated cell sorting as previously described. 22 Experiment was repeated at least three times and a representative picture is presented. (d) MCF7 cells were transfected with the indicated shRNA and after 24 h were treated with ALLN and exposed to 10 Gy of IR as above. Following ethanol fixation, cells were permeabilized and stained with rabbit polyclonal antibody against phosphor-ser10 histone H3 followed by goat anti-rabbit conjugated to Alexa488 and propidium iodide. Fraction of mitotic cells was determined by percentage of costained cells. Results shown are average of three independent experiments. Error bars represent s.d. ** Po0.01. (e) BRCA1-deficient and -proficient MCF7 cells were treated with of MG132 for 1 h and then irradiated with the indicated doses of IR. Cells were let to recover for 1 h and then were split in a limiting dilution. After 12-14 days, the dishes were stained with crystal violet and colonies with more than 50 cells were counted. Experiments were done in triplicates; results shown are average of three independent experiments. Error bars indicate s.d. (f ) WT-BRCA1 or I26A or C61G BRCA1 mutants were transfected into HCC1937 or BRCA1-silenced MCF7 cells, and 24 h later were treated with 40 ng/ml of the radiomimetic drug neocarzinostatin (NCS) and ALLN. Treatments were washed out after 12 h and cells were allowed to continue to grow. Cell viability was measured after three days. Relative changes are expressed as normalized values of crystal violet staining in treated cells compared with vehicle-treated controls. Results shown are average of three independent experiments. Error bars indicate s.d. *Po0.02; **Po0.001. ubiquitination (self autoubiquitination or by another E3 ligase) to cause their sedimentation. Analysis of the insoluble complexes in cell pellets revealed that BRCA1 is heavily modified and might be mislocalized in the proteasome inhibitor-treated cells (Supplementary Figure S6) .
BRCA1 mediates cyclin B and Cdc25C ubiquitination
To confirm that BRCA1 promotes ubiquitination of cyclin B and Cdc25C in cells, ubiquitinated cyclin B was detected by immunoprecipitation followed by two parallel immunoblots probed with either an antibody directed against ubiquitin or an antibody against cyclin B. Characteristic polyubiquitin laddering was detected in BRCA1-proficient cells that were treated with proteasome inhibitor (Figure 4a upper panel) . A similar laddering pattern was observed for cyclin B (Figure 4a lower panel) . To determine whether cyclin B ubiquitination is enhanced in response to DNA damage, we repeated the experiment in cells that were treated with ALLN and exposed to IR (Figure 4b ). Increased levels of ubiquitin-conjugated cyclin B were detected in IR-treated HCC1937-BRCA1 cells but not in HCC1937 control cells (Figure 4b) .
To verify the role of BRCA1 in de-novo polyubiquitination of cyclin B, BRCA1-proficient and -silenced MCF7 cells were transfected with HA-tagged ubiquitin. The appearance of newly formed HA-ubiquitin chains on cyclin B was detected by immunoprecipitation of cyclin B followed by immunoblot using an antibody against the HA tag. In the absence of BRCA1 expression, there was no efficient polyubiquitination of cyclin B (Figure 4c ). To date, conjugation via lys6 (K6) was mostly reported in the context of BRCA1-mediated in vivo polyubiquitination. 15, 16, 33 Here, we show that BRCA1/BARD1 ubiquitination of cyclin B does not occur via K6 ubiquitin chain assembly as no polyubiquitination can be observed when a mutant K6 only HAUb (gift of T Ohta) was transfected into MCF7 cells (Figure 4c ).
Given the rapid and transient nature of ubiquitination reactions and the fact that BRCA1 is part of a single RING family of E3 ligases that only facilitates the transfer of activated ubiquitin from an E2 enzyme to its substrate, we cross-linked proteins in cells treated with ALLN and with the radiomimetic drug neocarzinostatin and carried out an immunoprecipitation of BRCA1 that was followed by immunoblots with antibodies to cyclin B or BRCA1. We found an association between cyclin B and BRCA1 in untreated cells that increases in response to DNA damage (Figure 4d) . The extracts that were depleted of BRCA1 by the immunoprecipitation showed no residual cyclin B (Figure 4d) .
Next, we carried out cell-free ubiquitination reactions combining immunoprecipitated BRCA1 from BRCA1-proficient HCC1937 cells, purified recombinant His-tagged cyclin B or His-tagged Cdc25C as substrates and recombinant E1 ubiquitin-activating enzyme, E2 ubiquitin-conjugating enzyme (UbcH5c) and HAubiquitin. An extract of HCC1937 vector cells was preincubated with anti-BRCA1 antibody and was utilized as a negative control. The level of ubiquitination was determined by immunoblotting with an anti-HA antibody. Data in Figure 4e show that Cdc25C was polyubiquitinated with HA-ubiquitin chains only when all reaction components were included. Ubiquitination of Cdc25C was not detected in the absence of recombinant E1 and E2 enzymes, BRCA1 or when the substrate was not included (Figure 4e) . Moreover, prior exposure of HCC1937-BRCA1 cells to IR enhanced BRCA1-mediated Cdc25C polyubiquitination (Figure 4e) . To confirm the polyubiquitination of Cdc25C, we re-probed the membrane with anti-Cdc25C antibody. A strong correlation is observed between the HA and the Cdc25C ubiquitination pattern, further supporting de-novo ubiquitination of Cdc25C by BRCA1. The presence of equal amounts of BRCA1 and BARD1 in the immunoprecipitates was confirmed by immunoblot analyses using anti-BRCA1 antibody (Figure 4e ) and anti-BARD1 antibody (Figure 4e) . In a similar cell-free assay cyclin B is polyubiquitinated with HA-ubiquitin chains only when all reaction components are assembled together. In the absence of either wild-type BRCA1, E1 or E2 (UbcH5c), cyclin B is not ubiquitinated efficiently (Figure 5a ). DNA damage enhances cyclin B polyubiquitination (Figure 5a ). Together these results support the hypothesis that BRCA1 is required for ubiquitination of cyclin B and Cdc25C, and polyubiquitination is enhanced following exposure to IR and hydroxyurea in BRCA1-proficient cells only. BRCA1 was shown to be modified by both phosphorylation and sumoylation in response to DNA damage, thus, it is feasible that these modifications enhance its activity.
BRCA1 collaborates with UbcH1 to ubiquitinate cyclin B BRCA1 has been shown to interact with 10 different E2-activating enzymes, which catalyze a variety of chain topologies. Of those enzymes few were found to productively collaborate with BRCA1 On the following day, cells were treated with ALLN as described and some cells were exposed to 10 Gy IR or hydroxyurea (HU). Detection of HA-ubiquitin chains on cyclin B was carried by immunoprecipitation with a polyclonal antibody against cyclin B followed by immunoblot with a monoclonal antibody against HA-tag. (d) DNA damage enhances the association between BRCA1 and cyclin B. MCF7 cells were treated with ALLN and the radiomimetic drug, neocarzinostatin (NCS), for 4 h. Proteins were cross-linked with 1% formaldehyde for 10 min before the reaction was stopped. Cells were lysed and the association between BRCA1 and cyclin B was analyzed by immunoprecipitation with a monoclonal antibody against BRCA1 followed by immunoblot with a polyclonal antibody against cyclin B or a monoclonal antibody against BRCA1. Recombinant His-tagged cyclin B purified from bacterial extract was used as a control. Normal mouse IgG (NMIgG) was used as a negative control. Input represents total cell lysates and depleted lanes represent a fraction of the proteins that were not precipitated with the antibody against BRCA1. (e) BRCA1 polyubiquitinates Cdc25C in cell-free extracts. BRCA1 was immunoprecipitated from HCC1937-BRCA1 cell lysates. Following extensive washing, the precipitate was incubated in 30 ml ubiquitination reaction buffer together with purified His-Cdc25C, HA-Ub, E1, E2 (UbcH5c) and ATP. Immunoprecipitation with anti-BRCA1 antibody of HCC1937 cell lysate was used as a negative control. Following 1 h incubation, reaction mix were resolved on SDS-polyacrylamide gel electrophoresis and immunblotted with anti-HA antibody or with anti-Cdc25C antibody. Amounts of BRCA1 and BARD1 in these lysates were detected with their corresponding antibodies (lower panels).
in its autoubiquitination. 34 To determine which E2 collaborates with BRCA1 in promoting cyclin B ubiquitination, we repeated the cell-free ubiquitination assays as described above with the two E2s that are involved in conjugation of polyubiquitin chains: UbcH1(ube2k) and MMS2-Ubc13 complex. We found that in addition to the promiscuous E2: UbcH5c, UbcH1, which catalyzes K48 chains, was able to promote BRCA1-dependent ubiquitination of cyclin B that is enhanced following exposure to DNA damage. On the other hand, MMS2-UbcH13 complex that catalyzes K63 chains was able to promote ubiquitination in a BRCA1-independent manner (Figures 5 a-c) . To verify that cyclin B ubiquitination is mediated by BRCA1 and UbcH1, we silenced UbcH1 expression in wild-type and BRCA-deficient MCF-7 cells and analyzed whether cyclin B could be ubiquitinated in response to IR. Results presented in Figure 5d show that cyclin B ubiquitination increased only in cells that express BRCA1 and UbcH1, whereas levels of cyclin B ubiquitination were reduced in UbcH1-or BRCA1-silenced cells (Figure 5d ). These results suggest that BRCA1 targets cyclin B to the proteasome via the canonical ubiquitination pathway. As a control we analyzed the ubiquitination levels of histone H2A and found that although levels are slightly reduced in BRCA1-silenced cells, IR or proteasome inhibitor had almost no effect in either BRCA1-proficient or -silenced cells, whereas the combination of treatments caused slight decrease in ubiquitinated H2A (Supplementary Figure S7) . Silencing of UbcH1 also had very little effect on levels of ubiquitinated H2A (Figures 5d-f ).
To further demonstrate that BRCA1 directly ubiquitinates cyclin B, we reconstituted in vitro ubiquitination reactions with purified recombinant BRCA1 RING domain and full length of BARD1 as the only source of an E3 ligase activity. As a control substrate, we used a purified histone fraction. Results shown in Figure 5g suggest that the greatest extent of cyclin B polyubiquitination occurs in vitro only when all reaction components are present and not when E1, E2 (UbcH5c), cyclin B or BRCA1 are missing. Furthermore, the BRCA1 mutant C61G does not support cyclin B ubiquitination in vitro. Here again, we assayed several of the E2 enzymes including UbcH1, UbcH10 and UbcH13-MMS2. Both UbcH1 and UbcH10 can catalyze K48 polyubiquitin chains but the latter does not interact with BRCA1. No ubiquitination was detected with UbcH13-MMS2 complex (data not shown), and no specific cyclin B ubiquitination was seen with HCC1937-BRCA1 cells were exposed to DNA damage (10 Gy IR or hydroxyurea), and BRCA1 was immunoprecipitated from cell lysates. Following extensive washing the precipitate was incubated in 30 ml ubiquitination reaction buffer together with purified His-cyclin B, HA-Ub, E1, E2 and ATP. Immunoprecipitation with anti-BRCA1 antibody of HCC1937 cell lysate was used as a negative control. Following 1-h incubation reaction mix were resolved on SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotted with anti-HA antibody. (d) Control and shBRCA1-MCF7 cells were transfected with control (cyclophillin) siRNA or specific siRNA targeting UbcH1 (Ube2k) for 48 h. Cells were then pre-treated with ALLN for 1 h followed by 10 Gy IR. Cells were let to recover for 4 h. Ubiquitinated proteins were immunoprecipitated with a mouse monoclonal antibody against ubiquitin. Ubiquitination of cyclin B was determined by an immunoblot using an antibody against cyclin B. Silencing of UbcH1 was confirmed by immunoblot (lower panel). (e) Control and shBRCA1-MCF7 cells were transfected with control (cyclophillin) or UbcH1-specific siRNA. Cells were collected at 48 h after transfection and immunoblot analysis was carried out for the indicated proteins. (f ) Control and shBRCA1-MCF7 cells were transfected with control (cyclophillin) or UbcH1-specific siRNA. Cells were then pre-treated with 10 mM of MG132 and then with 10 Gy of IR. Cells were let to recover for 4 h and then collected for immunoblot analysis of the indicated proteins. (g) Purified recombinant histidine-tagged BRCA1 (RING domain within 1-304 aa), His-BARD1 (full length) and His-cyclin B (full length) were combined in 30-ml ubiquitination reaction buffer together with HA-Ub, E1, E2 and ATP. Following 1-h incubation reaction mix were resolved on SDS-PAGE and immunoblotted with anti-HA antibody. As a negative control, the RING domain mutant BRCA1 (C61G) was used as the source of E3 ligase activity.
UbcH10 (Figure 5g ). Cyclin B ubiquitination was detected with both UbcH5c and UbcH1. Although UbcH5c ubiquitinates histone proteins, the reaction with UbcH1 appears to be more specific to BRCA1. Together, our data suggest that BRCA1-dependent ubiquitination of cyclin B and H2A are modulated by two independent mechanisms even in response to DNA damage.
The topology of ubiquitin linkage catalyzed on cyclin B was elucidated by excision of in vitro-ubiquitinated cyclin B band from an SDS-polyacrylamide gel electrophoresis, followed by in-gel tryptic digestion and analysis by MALDI-TOF MS and nano-LC-ESI-MS/MS. Along with the ubiquitinated peptides originated from cyclin B identifying its acceptor sites (Supplementary Table S1 ), two 'signature' ubiquitinated peptides of ubiquitin incorporating lysine residues at positions 48 and 33 were located by their mass shifts in both MALDI-TOF and ESI-MS analyses and using Mascot database (Supplementary Table S2 ).
BRCA1 ubiquitinates cyclin B independent of the cyclosome APC/C Both cyclin B and Cdc25C are known degradable substrates of the cyclosome APC/C. Cyclin B ubiquitination by APC/Cdc20 facilitates its proteasomal degradation during metaphase whereas Cdc25C ubiquitination is mediated by APC/Cdh1 upon mitotic exit. We expressed wild-type and APC/C-resistant cyclin B (destruction box (D-box)-mutant, gift of M Brandeis, 35 ) in BRCA1-deficient andproficient HCC1937 cells (Figure 6a) . We show by immunoblot analysis that wild-type cyclin B expression is downregulated in Figure 6 . BRCA1 targets cell cycle proteins for degradation via the proteasome independently of APC/C. (a) BRCA1 does not recognize the APC/C degron. BRCA1-deficient and -proficient HCC1937 cells were transfected with GFP fusion wild-type or destruction box-mutant cyclin B. After 24 h, cells were collected and expression levels of cyclin B were determined by immunoblotting. a-Tubulin reveals equal loading. (b) HCC1937 cells were co-transfected with Ad-BRCA1 and wild-type or lysine mutant of cyclin B expression vector. Twenty-four hour after transfection, cells were exposed to 10 Gy and let to recover for additional 24 h. Cells were fixed and stained with propidium iodide for cell cycle analysis as described. (c) BRCA1 regulates MAD2 mRNA expression. HCC1937 vector and HCC1937-BRCA1 cells were exposed to IR (10 Gy). Cells were let to recover for the indicated times and total RNA was obtained and reversed transcribed. qRT-PCR analysis of MAD2 was carried in the presence of SybrGreen and normalized against GAPDH expression. Experiments were repeated at least three times and results are presented as mean±s.d. *Po0.05, **Po0.02. (d) BRCA1 regulates MAD2 protein expression. HCC1937 vector HCC1937-BRCA1 cells were exposed to IR (10 Gy) and collected at the indicated times. Expression levels of MAD2 were analyzed by immunoblot while GAPDH levels reveal equal loading. (e) BRCA1 regulates USP44 mRNA expression. HCC1937 vector and HCC1937-BRCA1 were exposed to 10 Gy IR, and cells were let to recover for the indicated times and total RNA was obtained and reversed transcribed. qRT-PCR analysis of USP44 was carried in the presence of SybrGreen and normalized against GAPDH expression. Experiments were repeated at least three times and results are presented as mean±s.d. *Po0.05 cells proficient for BRCA1 compared with BRCA1-deficient background. Interestingly the expression of the APC/C non-degradable cyclin B mutant substrate expression was downregulated in BRCA1-proficient cells (Figure 6a ), implying that BRCA1 targets cyclin B to the proteasome independently of APC/C.
To assess the contribution of specific lysine residues that were identified as BRCA1-dependent cyclin B acceptor sites to cell cycle arrest following IR, we have generated mutant cyclin B constructs in which lysine residues were replaced by arginine residues. Wildtype and mutant cyclin B recombinant proteins were ectopically expressed together with wild-type BRCA1 and transfected HCC1937 cells were exposed to 10 Gy of IR. Expression of cyclin B proteins caused accumulation of cells in the G2/M phase of the cell cycle (Figure 6b) . In response to IR, additional accumulation of cells in the G2/M phase was observed for wild-type cyclin B expressing cells. However, mutant cyclin B proteins in which lysine residues 16 and 18 (K16, K18) or lysine 63, lysine 64 (K63, K64) and or lysine 67 (K64, K67) were mutated did not support any further accumulation of cells in the G2/M phase of the cell cycle. Thus, expression of mutant cyclin B enabled the cells to bypass the G2/M checkpoint regardless of the presence of wild-type BRCA1 (Figure 6b ). In contrast, mutations of lysine residues 51 and 59 (K51, K59) did not impair the accumulation of cells at the G2/M phase following DNA damage. Taken together, lysine residues K16, K18, K63, K64 and K67 in cyclin B seem to have an important role in BRCA1-mediated cell cycle arrest.
MAD2 is a pivotal component of the SAC. 25 MAD2 inhibits APC/Cdc20-dependent degradation (including cyclin B) before mitosis to prevent chromosome missegregation. 36 Our results indicate that BRCA1 upregulates MAD2 mRNA and protein expression especially following exposure to IR (Figures 6c and d ) in human cells as was shown previously in murine cells. 37 In addition we found that BRCA1 upregulates another SAC protein: the deubiquitinating enzyme, USP44 (Figure 6e ). USP44 deubiquitinates Cdc20 and enables the stabilization of the inactive complex MAD2-CDC20-APC/C. 38 Taken together, our results show that BRCA1 modulates the expression of at least two SAC members (MAD2 and USP44) in addition to ubiquitinating Cdc25C and cyclin B, and targeting them for proteasomal degradation (Figure 7) . DISCUSSION BRCA1 was the first E3 ligase identified at sites of double-strand break following DNA damage. Yet, the current list of BRCA1 ubiquitinated substrates does not provide many clues as to how BRCA1 E3 ligase activity contributes to cellular responses following DNA insults. Here, we show that BRCA1 promotes polyubiquitination and degradation of two essential cell cycle proteins, cyclin B and Cdc25C, that are critical for the transition of cells from the G2 phase to the M phase. BRCA1 promotes their ubiquitination via the ubiquitin-proteasome pathway especially following DNA damage. Our data offer a mechanistic insight into the role of BRCA E3 ligase in preventing unscheduled mitotic entry (the uncoupling between DNA repair completion and mitosis) and maintenance of genome stability.
The limiting step for cell cycle transition into mitosis is the activation of the cyclin B/Cdk1 complex. The temporal cyclin BCdk1 complex formation is tightly regulated by several cellular mechanisms including inhibition of cyclin B1 transcription, 39 spatial control of cyclin B1-Cdk1 and Cdc25B/C, 40, 41 and targeted Cdc25C destruction. 26, 28 Here, we show that BRCA1 is critical for cyclin B and Cdc25C ubiqutination and accelerated turnover. We show that BRCA1 downregulates cyclin B expression even in the presence of Chk1 inhibition with UCN-01, inferring to multiple levels of direct and indirect cell cycle regulation by BRCA1. Interestingly, it was recently suggested that BRCA1 involvement in the DNA damage response could be divided between activities that require its catalytic activity versus those that do not. 42 Furthermore, an inverse correlation between BRCA1 and cyclin B expression was noted in many breast tumors. 43 We found that the RING finger together with the C-terminus BRCT domain and the adjacent phosphorylation sites are required for efficient ubiquitination and degradation of cyclin B and Cdc25C via the proteasome. These domains were shown to be important for IR-induced foci and G2/M checkpoint activation. 30 In vitro, the RING domain was sufficient to promote cyclin B ubiquitination. Similar to an observation for which the C-terminus of BRCA1 was dispensable for in vitro ubiquitination of RNA Polymerase II. 18 The requirement for the C-terminal BRCT domain in the cells may suggest that in the complex environment of the nucleus, DNA-damage-induced post-translational modifications of BRCA1 such as phosphorylation and sumoylation 4, 44 may activate its E3 ligase activity either by altering the protein conformation or by facilitating its binding with its substrates.
Our data suggest that the ubiquitination function of BRCA1 at the amino-terminus is required to protect cells from DNA-damageinduced cell death, as overexpression of two BRCA1 ubiquitination defective mutants (I26A and C61G) decrease cell survival compared with overexpression of wild-type BRCA1. Yet recently it was reported that I26A mutation has limited phenotypic effect in murine models and is dispensable for DNA repair 45, 46 In contrast, a recent report by Zhu et al 13 demonstrated that BRCA1-mediated ubiquitination of H2A is critical for heterochromatin silencing and maintenance of genomic stability whereas the I26A mutant failed to support this activity. The basis for the discrepancies is unclear and could result from the different model systems used in the different studies especially considering that murine models of BRCA1 require two allelic deletions and loss of p53 to induce tumor formation. 47, 48 Thus, it is possible that murine cells have additional protective mechanisms to suppress genomic instability when Brca1 is mutated. In further support of cyclin B as a physiological substrate of BRCA1 and the importance of this mechanism for maintenance of genomic stability, we show that overexpression of specific cyclin B ubiquitination mutants allow IR-treated BRCA1-proficient cells to bypass the G2/M checkpoint with cell cycle distribution similar to non-damaged cells or BRCA1-deficient cells. Interestingly, we identified K63 and K64 as part of a small ubiquitin-like modifier consensus binding site in cyclin B, which may explain why mutations of these residues will abrogate BRCA1 activity.
The chemical nature of the ubiquitin linkage catalyzed by the BRCA1/BARD1 complex is another point of contention. Monoubiquitination substrates include the histone proteins, H2A and H2AX, g-tubulin and ER-a. 3, 11, 12, 49, 50 The BRCA1/BARD1 complex can also catalyze and assemble polyubiquitin chains through K6, 16, 31 K48 and K63. 4 Poly-autoubiquitination stabilizes the BRCA1/BARD1 complex and enhances its polyubiquitination. BRCA1 polyubiquitinates the G2/M-related proteins NPM/B23 16 and CtIP 31 via the unconventional K6 chains, and these substrates are not targeted for proteasomal degradation. Hence, it is difficult to assess the contribution of K6 assembled chains to the DNA damage response. The versatility of BRCA1 in promoting multiple types of ubiquitin linkage is not unique and additional E3 ligase enzymes have similar capabilities. For example, Parkin, a RING E3 ligase, catalyzes K48 and K63 links. 51 APC/C was shown to catalyze mono-Ub, K-63-linked, K-11-linked and K-48-linked ubiquitin chains all on one substrate: cyclin B. Interestingly, all modifications signaled for proteasomal degradation with similar kinetics even in the absence of K-48-linked ubiquitination. 52 MALDI-TOF and ESI-MS analysis revealed that BRCA1-mediated ubiquitin chain assembly via K48 or K33 on cyclin B rather than K6. As different E2 enzymes can direct BRCA1 to catalyze different types of ubiquitin chains, 34 we assessed the ability of four different E2 enzymes (UbcH5c, UbcH1, Ubc13-MMS2 and UbcH10) to support BRCA1-dependent cyclin B ubiquitination. In addition to the promiscuous E2, UbcH5c, which supports assembly of both mono and several types of polyubiquitin chains, UbcH1, which promotes K48 polyubiquitin chain assembly supported BRCA1-mediated cyclin B polyubiquitination. Furthermore, silencing of UbcH1 diminished BRCA1-dependent ubiquitination of cyclin B but did not affect H2A ubiquitination. Not surprisingly, UbcH10, which support K48 chains assembly but does not bind BRCA1, did not support BRCA1-dependent cyclin B ubiquitination. 34 In summary, this study shows that BRCA1 binds to and ubiquitinates cyclin B and Cdc25C, and targets them for degradation, a function which is enhanced in response to DNA damage. Mutant BRCA1 and mutant cyclin B proteins abrogate these interactions and fail to prevent unscheduled mitotic entry and fail to support proper cell cycle regulation. BRCA1 also modulates the expression of at least two SAC proteins (MAD2 and USP44) and therefore adopts a multi-modal approach to bring about G2 arrest in response to DNA damage. This study is the first to demonstrate the importance of BRCA1-dependent cyclin B and Cdc25C ubiquitination in DNA damage-induced G2 arrest and may provide an insight not only to mechanisms that are responsible for tumor prevention but also for how tumor cells may escape therapy.
MATERIALS AND METHODS
Cell culture and treatments
All cell lines were cultured in Dulbecco's modified Eagle's medium with 10% fetal calf serum. Proteasome inhibitors ALLN or MG132 were dissolved in dimethyl sulfoxide and added to the culture medium at a concentration of 10 mM. CHX was added to the culture medium at a concentration of 50 mg/ml. For DNA damage, cells were either exposed to IR from 137 Cesium source (gcell irradiator) or 40-120 ng/ml of Neocarzinostatin (Sigma, St Louis, MO, USA) or 2 mM hydroxyurea (Sigma).
Plasmids and transfections
Detailed information about the plasmids utilized in this study is provided as Supplementary Information. Supplementary Table S3 provides the primer sequences for cloning.
Protein cross-linking
Proteins in MCF7 cells were cross-linked with 1% formaldehyde at 30 o C for 10 min. Cross-linking was stopped by the addition of ice-cold 0.1 M glycine. Cells were lysed in 1 ml of ice-cold NETN buffer supplemented with EDTAfree protease inhibitor cocktails (Calbiochem, Billerica, MA, USA). Cell lysates were clarified by centrifugation at 4 1C for 30 min at 10 000 g.
Immunoblotting, immunoprecipitation and immunofluorescence
Immunoblots, immunoprecipitations and Immunofluorescence assays were carried out as previously described. 53 Information on the antibodies used in this study is listed in the Supplementary Information.
Cell cycle analysis Cells (2 Â 10 6 ) were resuspended in ice-cold ethanol (70% (v/v)) and incubated overnight at À 20 o C. Before analysis, cells were washed twice with phosphate-buffered saline, incubated in 1 ml of 40 mg/ml propidium iodide (Sigma), 50 ml/ml RNase A and 0.1% (v/v) Triton X-100 in phosphatebuffered saline for 15 min at 37 1C. Cell cycle profiles and cellular fluorescence were acquired on a fluorescence-activated cell sortingCalibur instrument (Becton Dickinson, Franklin Lakes, NJ, USA) using FACSDiva Software 6.0 (BD Biosciences, San Jose, CA, USA).
The fraction of mitotic cells was determined by permeabilizing the cells with Triton-X-100 and followed by staining with rabbit polyclonal antibody against phosphor-ser10 histone H3 and with goat anti-rabbit IgG conjugated to Alexa488.
Site-directed mutagenesis
Site-directed mutagenesis of human cyclin B cloned in pEGFP was carried out with QuikChange lightning kit (Agilent, Santa Clara, CA, USA) according to the manufacturer's instructions. Primer sequences are described in the Supplementary Table S4. RNA isolation and quantitative reverse transcription PCR Total RNA was isolated from cells using TRIZOL (Invitrogen, Carlsbad, CA, USA). Complementary DNA was synthesized using Superscript II according to the manufacturer's instructions (Invitrogen). Real-time PCR of samples was done using an ABI7900HT sequence detection system (Applied Biosystems, Grand Island, NY, USA) in the presence of SYBRgreen (Qiagen, Valencia, CA, USA). Experiments were performed in triplicate, data were normalized to the housekeeping gene, GAPDH, and the relative abundance of transcripts was calculated by the comparative DDCt method. All primer sequences are available in the Supplementary Table S5 in the Materials and Methods section.
Recombinant protein purification
Histidine-tagged-cyclin B and histidine-tagged Cdc25C were expressed from pET-cyclin B and pET-CDC25C, and produced in BL21 (PLysS-DE3) cells following induction with 1 mM IPTG for 3 h. The recombinant polypeptides were purified from clarified extracts on Ni-NTA resin (Novagen, Billerica, MA, USA) and eluted with 0.6 M imidazole according to the standard protocols and as previously described. 53 Cell-free ubiquitination assay BRCA1 was immunoprecipitated from cell extract of treated and untreated cells. Following extensive washing under stringent conditions, the purified precipitate was incubated in 30 ml ubiquitination buffer (50 mM Tris-Cl pH ¼ 7.8, 5 mM MgCl 2 , 2mM NaF, 0.6 mM DTT, 0.5 mM EDTA), including 150 ng of purified recombinant His-Cdc25c or His-cyclin B, 5 mM HA-ubiquitin, 300 ng E1 and 300 ng E2 (UbcH5c; UbcH1; Ubc13-MMS2) and ATP (ERS, Boston Biochem, Cambridge, MA, USA), at 30 o C for 1 h. Reaction products were resolved on SDS-polyacrylamide gel electrophoresisPAGE electrophoresis and probed with anti-HA antibody and antiCdc25C antibody, as well as anti-BRCA1 and anti-BARD1 antibodies. For reconstituted in vitro ubiquitination assays, 300 ng of purified recombinant His-BRCA1 (1-304 aa) and His-BARD1 (full length) were incubated with 150 ng of purified recombinant His-cyclin B, 5 mM HA-ubiquitin, 300 ng E1 and 300 ng E2 (UbcH5c; UbcH1, Ubc13-MMS2; UbcH10), and ATP (ERS) (all purchased from Boston Biochem) in 30 ml ubiquitination buffer at 30 o C for 1 h. Reaction products were resolved on SDS-polyacrylamide gel electrophoresis and probed with anti-HA antibody.
Histone extraction
Histones were extracted from cells lysed in phosphate-buffered saline supplemented with 0.5% Triton 100 Â and a cocktail of protease and phosphatase inhibitors. Cell pellets were resuspended in 0.2 N HCl and extraction proceeded with overnight incubation. Samples were cleared by centrifugation 2000 r.p.m., supernatant were precipitated overnight with 10 v/v of acetone and resuspended in sample buffer.
In-gel digestion, mass spectrometry and nano-LC-ESI-MS/MS Detailed information on mass spectrometry analysis is provided in the Supplementary Information.
Ubiquitination and proteasomal degradation S Shabbeer et al
Statistical analysis
Each experiment was repeated at least three times. Quantitative data were expressed as the mean±s.d. Group data were analyzed by one-way analysis of variance. A value of Po0.05 between groups were considered statistically significant.
